A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants

This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.

Start Date07 Dec 2016

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)

100 Translational Medicine associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)

100 Patents (Medical) associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)

Literatures (Medical) associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)

01 Dec 1979·Journal of Infectious DiseasesQ2 · MEDICINE

Kinetics of Antibody Production to Group A and Group C Meningococcal Polysaccharide Vaccines Administered during the First Six Years of Life: Prospects for Routine Immunization of Infants and Children

Q2 · MEDICINE

Article

Author: Martha L. Lepow ; Irving Goldschneider ; Thomas F. Draper ; Ronald Gold ; Emil C. Gotschlich

A cohort of infants, previously immunized once or twice between three and 12 months of age with vaccines containing polysaccharide of groups A and C Neisseria meningitidis, received boosters at two and five and one-half years of age with bivalent A/C vaccine. Antibody concentrations were measured by a radioactive antigen-binding assay. Concentrations of antibody to groups A and C N. meningitidis were 5.59 and 2.86 microgram/ml, respectively, by four years of age. After booster immunization at five and one-half years of age, concentrations of antibody to groups A and C N. meningitidis increased to 15.67 and 7.59 microgram/ml, respectively. Protective levels of antibody to group A meningococci may be achievable throughout early childhood by routine immunization with the A vaccine. Although the group C vaccine is effective in control of epidemics, the rapid decline in the concentration of antibody to group C meningococci following immunization of young children suggests that protection may not be long-lasting.

100 Deals associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	ZA	National Institute of Allergy & Infectious Diseases	07 Dec 2016
HIV Infections	Phase 2	US	National Institute of Allergy & Infectious Diseases	07 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02915016 (HVTN108, CTgov)	Phase 1/2	HIV Infections	334	Placebo+DNA-HIV-PT123 vaccine+Bivalent Subtype C gp120/MF59 vaccine (Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59)	kzdgcgvugm(hjxslcnqmp) = syafvfiege xrvzxuieev (ptfduehzuv, hkxrluhray - ysuqzfttzt) View more	-	16 Sep 2020
				Placebo+Bivalent Subtype C gp120/AS01B vaccine+DNA-HIV-PT123 vaccine (Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B)	kzdgcgvugm(hjxslcnqmp) = kfehndzfgg xrvzxuieev (ptfduehzuv, nxaavngoki - sabqrurayv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation